Our Team

  • Liliana Galindo, MD, PhD

    CHIEF PRINCIPAL INVESTIGATOR

    Affiliated Assistant Professor of Psychiatry and Director of the Cambridge Psychedelic Research Group, University of Cambridge; Consultant Psychiatrist and Medical Leader in Psychosis, Cambridgeshire and Peterborough NHS Foundation Trust (CPFT)

    SITE: Cambridge, England

  • Anya Ragnhildstveit, PhD(c)

    COORDINATING INVESTIGATOR

    Chief Executive Officer, Center for Psychedelic Research, Pneuma Science; Clinical Trial Dosing Session Monitor (Cybin, MindMed), Inner Space Research; PhD Candidate in Psychiatry (Eating Disorders), University of Cambridge

    SITE: Cambridge, England

  • Dasha Nicholls, MD

    SITE PRINCIPAL INVESTIGATOR

    Professor of Child and Adolescent Psychiatry, Imperial College London; Honorary Consultant Psychiatrist, Central and North West London NHS Foundation Trust (CNWL); National Speciality Advisor on All Age Eating Disorders, NHS England

    SITE: London, England

  • Victoria Burmester, PhD

    SITE CO-PRINCIPAL INVESTIGATOR

    Postdoctoral Research Associate in Psychiatry, Child and Adolescent Mental Health Group, Imperial College London; Clinical Product Developer for Eating Disorder Treatment, Univa Health

    SITE: London, England

  • David Nutt, MD

    SENIOR CO-INVESTIGATOR

    Edmond J. Safra Professor of Neuropsychopharmacology, Deputy Head of the Centre for Psychedelic Research, Imperial College London; Chair and Chief Scientific Officer, Drug Science

    SITE: London, England

  • David Erritzøe, MD, PhD

    SENIOR CO-INVESTIGATOR

    Clinical Senior Lecturer in Psychiatry and Director of the Centre for Psychedelic Research, Imperial College London; Consultant Psychiatrist and Director of the CNWL-Imperial Psychopharmacology and Psychedelic Research Clinic, St. Charles’ Hospital, CNWL NHS Foundation Trust

    SITE: London, England

  • Rayyan Zafar, PhD

    ADVISORY CO-INVESTIGATOR

    Postdoctoral Fellow in Neuropsychopharmacology, Centre for Psychedelic Research, Imperial College London; Senior Research Officer and Consultant, Medical Cannabis and Psychedelic Working Groups, Drug Science, Chief Scientific Officer, Moodeys

    SITE: London, England

  • Reid Robison, MD

    SITE PRINCIPAL INVESTIGATOR

    Chief Medical Officer, Inner Space Research; Chief Research Officer, Center for Psychedelic Research, Pneuma Science; Medical Director, Center for Change (Specialized Eating Disorder Treatment Center)

    SITE: Orem, Utah, United States

  • Camilla Lindvall Dahlgren, PhD

    CLINICAL CO-INVESTIGATOR

    Professor of Clinical Psychology, Head of Research, and Director of The Eating Disorders Lab, Oslo New University College (ONUC); Co-Director of the Ketamine Initiatives for Eating Disorders, (KITE) ONUC / Axonklinikken Clinic

  • Paul Seli, PhD

    SCIENTIFIC CO-INVESTIGATOR

    Chief Scientific Officer, Center for Psychedelic Research, Pneuma Science; Clinical Trial Dosing Session Monitor for Voyage Study (MM120-300), Panorama Study (MM120-301), and Approach Study (CYB003-002), Inner Space Research

  • Jamarie Geller, MD

    CLINICAL CO-INVESTIGATOR

    Chief Clinical Officer, Center for Psychedelic Research, Pneuma Science; Adjunct Clinical Assistant Professor of Psychiatry, Michigan Psychedelic Center, Department of Psychiatry, University of Michigan Medical School

  • Miriam Kaiyo, PhD

    SCIENTIFIC CO-INVESTIGATOR

    Chief Impact Officer, Center for Psychedelic Research, Pneuma Science; Adjunct Professor of Human Development and Social Policy, Department of Family and Consumer Studies, The University of Utah